NLS Nautilus Inc

Nautilus, Inc. Reports Results for the First Quarter 2017

May 1, 2017 - Nautilus, Inc. (NYSE: NLS) today reported its unaudited operating results for the first quarter ended March 31, 2017.

Q1 2017 Highlights

All comparisons relate to the first quarter of 2016 unless otherwise indicated:

  • Revenues:
    • Total revenue was $113.3 million compared to guidance range of $110 - $112 million and prior year of $120.9 million.
    • Direct segment sales decreased 8.0% to $74.7 million primarily due to lower TreadClimber® sales.
    • Retail segment sales decreased 2.6% to $37.8 million, reflecting the impact of certain customers rebalancing their inventory levels, coupled with some softness in the retail market.
  • Gross Margins:
    • Total company gross margins decreased by 40 basis points to 54.5% due to a shift in segment mix, reflecting an increased percentage of Retail sales.
    • Retail margins improved by 210 basis points due to favorable product mix.
  • Operating Expenses:
    • Operating expenses increased 440 basis points as a percentage of net sales with planned increases in sales, marketing, and product development, slightly offset by a decline in general and administrative costs.
  • Operating income of $12.7 million compared to guidance range of $12.5 - $14.0 million, and prior year of $19.3 million, with operating margin of 11.2%, down 480 basis points versus prior year.
  • Income from continuing operations for the first quarter of 2017 was $8.2 million, or $0.26 per diluted share, compared to income from continuing operations of $11.6 million, or $0.37 per diluted share.
  • EBITDA from continuing operations totaled $14.9 million compared to $21.1 million in the prior year period.
  • At March 31, 2017, the Company had cash and marketable securities of $88.8 million and debt of $60.0 million, compared to $79.6 million and $64.0 million, respectively, at December 31, 2016.

Bruce M. Cazenave, Chief Executive Officer, stated, “First quarter 2017 revenue and operating income was in-line with our expectations. As anticipated, the first quarter presented a difficult comparison to prior year, but we are pleased that underlying factors such as Direct segment response rates continue to improve versus the back half of last year, and new product launches are tracking as planned, developments which together position us well for a strong second half of 2017.”

Mr. Cazenave continued, “We are very excited about the upcoming launch of our newest Direct product, the Bowflex Hybrid Velocity Trainer. This unique product delivers cardio and strength training simultaneously in one effective workout, along with customized programming tailored to user needs. In our Retail segment, the upcoming launch of the Bowflex Cardio Performance series represents our first entries into higher price points on key retail cardio products, which will further augment our position in this channel. In addition, new Octane Fitness products, including the Airdyne X and another Zero Runner (the ZR7000) for commercial gyms are scheduled for introduction in Q3 2017. Based on these, and other planned new product introductions, as well as a more normalized media environment this year, we believe we are well positioned to return to double-digit growth in the back half of 2017.”

For further information, see “Results of Operations Information” attached hereto.

Segment Results

Net sales for the Direct segment were $74.7 million in the first quarter of 2017, a decrease of 8.0% over the comparable period last year. Direct segment sales were impacted by a decline in TreadClimber® product sales. Operating income for the Direct segment was $15.3 million for the first quarter of 2017, compared to $21.1 million in the first quarter of last year. Operating income was impacted by the decline in net sales and gross profits, coupled with increased spend in media. Gross margin for the Direct business declined by 80 basis points due to higher discounting of TreadClimber® products.

Net sales for the Retail segment were $37.8 million in the first quarter of 2017, a decrease of 2.6% when compared to $38.8 million in the first quarter last year. The decline reflected weakness in the retail market along with certain customers rebalancing their inventory levels. Operating income for the Retail segment was $2.2 million for the first quarter of 2017 compared to $3.9 million in the first quarter of last year. The decrease in Retail operating income was primarily due to a $1.2 million reserve related to a royalty dispute. Retail gross margin was 32.0% in the first quarter of 2017, compared to 29.9% in the same quarter of the prior year. The higher gross margins reflected improved product mix.

Royalty revenue in the first quarter 2017 was $0.7 million, compared to $0.9 million for the same quarter of last year. Royalty income for the prior year included a settlement from a certain licensee.

For further information, see “Segment Information” attached hereto.

Balance Sheet

As of March 31, 2017, the Company had cash and marketable securities of $88.8 million and debt of $60.0 million, compared to cash and marketable securities of $79.6 million and debt of $64.0 million at year end 2016. Working capital of $86.1 million as of March 31, 2017 was $1.1 million higher than the 2016 year-end balance of $85.0 million, as an increase in cash and marketable securities offset a decline in other working capital accounts. Inventory as of March 31, 2017 was $34.3 million, compared to $47.0 million as of December 31, 2016 and $36.8 million at the end of the first quarter last year.

For further information, see “Balance Sheet Information” attached hereto.

Share Repurchase Program

The Company announced today that its Board of Directors has authorized an additional $15 million share repurchase program, bringing the total authorization under existing programs to $25 million. The Company has completed approximately $5.4 million in total share repurchases under the $10 million program announced in May 2016. The balance of approximately $4.6 million under that program may be repurchased from time to time through May 4, 2018. Under the newly authorized program, shares of the Company’s common stock may be repurchased from time to time through April 25, 2019. Repurchases under the Company’s share repurchase programs may be made in open market transactions at prevailing prices, in privately negotiated transactions, or by other means in accordance with federal securities laws. Share repurchases will be funded from existing cash balances and repurchased shares will be retired and returned to unissued authorized shares. More details on the share repurchase program are included in a separate press release issued today.

Conference Call

Nautilus will host a conference call to discuss the Company’s operating results for the first quarter ended March 31, 2017 at 4:30 p.m. ET (1:30 p.m. PT) on Monday, May 1, 2017. The call will be broadcast live over the Internet hosted at http://www.nautilusinc.com/events and will be archived online within one hour after completion of the call. In addition, listeners may call (877) 780-3379 in North America and international listeners may call (719) 325-2161. Participants from the Company will include Bruce M. Cazenave, Chief Executive Officer, Sid Nayar, Chief Financial Officer, and William B. McMahon, Chief Operating Officer.

A telephonic playback will be available from 7:30 p.m. ET, May 1, 2017, through 11:59 p.m. ET, May 15, 2017. Participants can dial (844) 512-2921 in North America and international participants can dial (412) 317-6671 to hear the playback. The passcode for the playback is 5307398.

Non-GAAP Presentation

In addition to disclosing results determined in accordance with GAAP, Nautilus has presented EBITDA from continuing operations, a non-GAAP financial measure, for the three months ended March 31, 2017 and 2016.

The Company defines EBITDA from continuing operations as its income from continuing operations, adjusted to exclude interest expense (income), income tax expense of continuing operations, and depreciation and amortization expense. The Company uses EBITDA from continuing operations in evaluating its operating results and for financial and operational decision-making purposes such as budgeting and establishing operational goals. The Company believes that EBITDA from continuing operations helps identify underlying trends in its business that could otherwise be masked by the effect of the items that are excluded from EBITDA from continuing operations and enhances the overall understanding of the Company’s past performance and future prospects. The Company presents EBITDA from continuing operations as a complement to results provided in accordance with GAAP, and these results should not be regarded as a substitute for GAAP. The Company strongly encourages you to review all of its financial statements and publicly-filed reports in their entirety and to not rely on any single financial measure.

For a quantitative reconciliation of our non-GAAP financial measures to the most comparable GAAP measures, see "Reconciliation of Non-GAAP Financial Measures" included with this release.

About Nautilus, Inc.

Headquartered in Vancouver, Washington, Nautilus, Inc. (NYSE: NLS) is a global fitness solutions company that believes everyone deserves a fit and healthy life. With a brand portfolio including Bowflex®, Nautilus®, Octane Fitness®, Schwinn® and Universal®, Nautilus, Inc. develops innovative products to support healthy living through direct and retail channels, as well as in commercial channels with Octane Fitness® products. Nautilus, Inc. uses the investor relations page of its website (www.nautilusinc.com/investors) to make information available to its investors and the market.

This press release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about projected or forecasted financial and operating results, statements regarding the Company's prospects, resources or capabilities; current or future financial and economic trends; future operating results; future plans for introduction of new products, channel diversification, anticipated response to media advertising; or anticipated demand for the Company's new and existing products. Factors that could cause Nautilus, Inc.’s actual results to differ materially from these forward-looking statements include failure to successfully integrate and realize anticipated benefits of acquired businesses, our ability to timely acquire inventory that meets our quality control standards from sole source foreign manufacturers at acceptable costs, greater than anticipated costs associated with launch of new products, incurrence of unanticipated obligations under licensing agreements, changes in consumer fitness trends, changes in the media consumption habits of our target consumers or the effectiveness of our media advertising, a decline in consumer spending due to unfavorable economic conditions and, softness in the retail marketplace. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission, including the “Risk Factors” set forth in our Annual Report on Form 10-K, as supplemented by our quarterly reports on Form 10-Q. Such filings are available on our website or at www.sec.gov. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events or circumstances.

RESULTS OF OPERATIONS INFORMATION

The following summary contains information from our consolidated statements of operations for the three months ended March 31, 2017 and 2016 (unaudited and in thousands, except per share amounts):

Three Months Ended

March 31,

2017   2016
 
Net sales $ 113,252 $ 120,928
Cost of sales 51,507   54,584  
Gross profit 61,745 66,344
 
Operating expenses:
Selling and marketing 37,665 35,179
General and administrative 7,486 8,231
Research and development 3,911   3,634  
Total operating expenses 49,062 47,044
 
Operating income 12,683 19,300
Other, net (360 ) (536 )
Income from continuing operations before income taxes 12,323 18,764
Income tax expense 4,138   7,178  
Income from continuing operations 8,185 11,586
Loss from discontinued operations(1) (1,092 ) (142 )
Net income $ 7,093   $ 11,444  
 
Basic income per share from continuing operations $ 0.27 $ 0.37
Basic loss per share from discontinued operations (0.04 )  
Basic net income per share $ 0.23   $ 0.37  
 
Diluted income per share from continuing operations $ 0.26 $ 0.37
Diluted loss per share from discontinued operations (0.04 )  
Diluted net income per share(2) $ 0.23   $ 0.37  
 
Shares used in per share calculations:
Basic 30,713 31,016
Diluted 31,127 31,295
 
Select Metrics:
Gross margin 54.5 % 54.9 %
Selling and marketing % of net sales 33.3 % 29.1 %
General and administrative % of net sales 6.6 % 6.8 %
Research and development % of net sales 3.5 % 3.0 %
Operating income % of net sales 11.2 % 16.0 %
 
(1) 2017 includes $1.2 million expense related to a lawsuit settlement with Biosig Instruments, Inc.
(2) May not add due to rounding.
 

SEGMENT INFORMATION

The following tables present certain comparative information by segment for three months ended March 31, 2017 and 2016 (unaudited and in thousands):

Three Months Ended

March 31,

  Change
2017   2016 $   %
Net sales:
Direct $ 74,703 $ 81,234 $ (6,531 ) (8.0 )%
Retail 37,805 38,805 (1,000 ) (2.6 )%
Royalty 744   889   (145 ) (16.3 )%
$ 113,252   $ 120,928   $ (7,676 ) (6.3 )%
 
Operating income (loss):
Direct $ 15,333 $ 21,144 $ (5,811 ) (27.5 )%
Retail 2,212 3,944 (1,732 ) (43.9 )%
Unallocated corporate (4,862 ) (5,788 ) 926   16.0 %
$ 12,683   $ 19,300   $ (6,617 ) (34.3 )%
 

BALANCE SHEET INFORMATION

The following summary contains information from our consolidated balance sheets as of March 31, 2017 and December 31, 2016 (unaudited and in thousands):

As of
March 31, 2017   December 31, 2016
Assets
 
Cash and cash equivalents $ 27,760 $ 47,874
Available-for-sale securities 61,053 31,743
Trade receivables, net of allowances of $136 and $170 24,870 45,458
Inventories 34,295 47,030
Prepaids and other current assets 6,986 8,020
Income taxes receivable 1,707   3,231
Total current assets 156,671 183,356
 
Property, plant and equipment, net 16,718 17,468
Goodwill 61,905 61,888
Other intangible assets, net 68,983 69,800
Deferred income tax assets, non-current 11
Other assets 513   543
Total assets $ 304,790   $ 333,066
 
Liabilities and Shareholders' Equity
 
Trade payables $ 39,408 $ 66,020
Accrued liabilities 12,162 12,892
Warranty obligations, current portion 3,040 3,500
Note payable, current portion 15,993   15,993
Total current liabilities 70,603 98,405
 
Warranty obligations, non-current 3,952 3,950
Income taxes payable, non-current 2,520 2,403
Deferred income tax liabilities, non-current 16,613 16,991
Other long-term liabilities 2,419 2,481
Note payable, non-current 43,984 47,979
Shareholders' equity 164,699   160,857
Total liabilities and shareholders' equity $ 304,790   $ 333,066
 

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

 

 

Three Months Ended

March 31,

2017   2016
 
Income from continuing operations $ 8,185 $ 11,586
Interest expense (income), net 313 412
Income tax expense of continuing operations 4,138 7,178
Depreciation and amortization 2,244   1,935
Earnings before interest, taxes, depreciation and amortization (EBITDA) from continuing operations $ 14,880   $ 21,111

EN
01/05/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nautilus Inc

MarketLine Department
  • MarketLine Department

iFIT Health & Fitness Inc - Company Profile and SWOT Analysis

Summary iFIT Health & Fitness Inc - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights iFIT Health & Fitness Inc (iFIT) is a fitness equipment manufacturer. The company's product portfolio includes treadmills, incline trainers, elliptical machines, stationary bikes, home gyms, w...

Nautilus Inc: 1 director

A director at Nautilus Inc bought 20,000 shares at 2.150USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

W WAYFAIR INC.
DHR DANAHER CORPORATION
VEEV VEEVA SYSTEMS INC CLASS A
USNA USANA HEALTH SCIENCES INC.
TSCO TRACTOR SUPPLY COMPANY
TBPH THERAVANCE BIOPHARMA INC
SMG SCOTTS MIRACLE-GRO COMPANY CLASS A
SLP SIMULATIONS PLUS
SLGN SILGAN HOLDINGS INC.
SFM SPROUTS FARMERS MARKETS INC.
RRC RANGE RESOURCES CORPORATION
RGEN REPLIGEN CORPORATION
RARE ULTRAGENYX PHARMACEUTICAL INC.
PYPL PAYPAL HOLDINGS INC
OLLI OLLIE'S BARGAIN OUTLET HOLDINGS INC
NLS NAUTILUS INC
NGVC NATURAL GROCERS BY VITAMIN COTTAGE INC
MTRN MATERION CORPORATION
MSCI MSCI INC. CLASS A
MOH MOLINA HEALTHCARE INC.
MMSI MERIT MEDICAL SYSTEMS INC.
MKTX MARKETAXESS HOLDINGS INC.
LMNX LUMINEX CORP
LDOS LEIDOS HOLDINGS INC.
INO INOVIO PHARMACEUTICALS INC.
HALO HALOZYME THERAPEUTICS INC.
HAE HAEMONETICS CORPORATION
GFI GOLD FIELDS LTD. ADS
GBT GLOBAL BLOOD THERAPEUTICS INC
FOLD AMICUS THERAPEUTICS INC.
EBS EMERGENT BIOSOLUTIONS INC.
CONE CYRUSONE INC.
CNC CENTENE CORPORATION
CIEN CIENA CORPORATION
CERS CERUS CORP.
CALX CALIX NETWORKS
BMRN BIOMARIN PHARMACEUTICAL INC.
AU ANGLOGOLD ASHANTI LTD. ADS
ASC ARDMORE SHIPPING
ALXN ALEXION PHARMACEUTICALS INC.
ALNY ALNYLAM PHARMACEUTICALS INC
ALLT ALLOT LTD
AGI. ALAMOS GOLD INC.
AAWW ATLAS AIR WORLDWIDE HOLDINGS INC.
MRVL MARVELL TECHNOLOGY GROUP LTD.
IRBT IROBOT CORPORATION
CCO. CAMECO CORPORATION
AEM. AGNICO EAGLE MINES LIMITED
NAT NORDIC AMERICAN TANKERS LIMITED
ENTG ENTEGRIS INC.
KLAC KLA CORPORATION
WERN WERNER ENTERPRISES INC.
MTSI MACOM TECHNOLOGY SOLUTIONS HOLDINGS INC.
WMK WEIS MARKETS INC.
FIZZ NATIONAL BEVERAGE CORP.
INSG INSEEGO CORP
PHI PHILIPPINE LONG DISTANCE TELEPHONE COMPANY ADS
OKTA OKTA INC. CLASS A
ARNA ARENA PHARMACEUTICALS INC.
QTRX QUANTERIX CORPORATION
SE SEA ADS
AMD ADVANCED MICRO DEVICES INC.
SWCH SWITCH
VICR VICOR CORP.
ALLO ALLOGENE THERAPEUTICS
TBIO TRANSLATE BIO
MR MONTAGE RESOURCES CORP.
BYND BEYOND MEAT
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
CLVT CLARIVATE PLC (A)
ATEX ANTERIX INC
ARCT ARCTURUS THERAPEUTICS HOLDINGS INC
SQNS SEQUANS COMMUNICATIONS ADR
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

RGLD ROYAL GOLD INC.
VRSN VERISIGN INC.
VNET 21VIANET GROUP INC. SPONSORED ADR CLASS A
TBPH THERAVANCE BIOPHARMA INC
SMG SCOTTS MIRACLE-GRO COMPANY CLASS A
SLP SIMULATIONS PLUS
SLGN SILGAN HOLDINGS INC.
SFM SPROUTS FARMERS MARKETS INC.
RGEN REPLIGEN CORPORATION
REGN REGENERON PHARMACEUTICALS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVDA NVIDIA CORPORATION
NLS NAUTILUS INC
MOH MOLINA HEALTHCARE INC.
LMNX LUMINEX CORP
JNJ JOHNSON & JOHNSON
IMMU IMMUNOMEDICS INC.
HALO HALOZYME THERAPEUTICS INC.
GFI GOLD FIELDS LTD. ADS
FOLD AMICUS THERAPEUTICS INC.
FAN FABRINET
FB FACEBOOK INC. CLASS A
EXEL EXELIXIS INC.
EBAY EBAY INC.
CTLT CATALENT INC
CHTR CHARTER COMMUNICATIONS INC. CLASS A
CDNS CADENCE DESIGN SYSTEMS INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
AU ANGLOGOLD ASHANTI LTD. ADS
ALNY ALNYLAM PHARMACEUTICALS INC
AGI. ALAMOS GOLD INC.
ACAD ACADIA PHARMACEUTICALS INC.
MRVL MARVELL TECHNOLOGY GROUP LTD.
SW SIERRA WIRELESS INC.
IRBT IROBOT CORPORATION
CCO. CAMECO CORPORATION
AEM. AGNICO EAGLE MINES LIMITED
NAT NORDIC AMERICAN TANKERS LIMITED
CMG CHIPOTLE MEXICAN GRILL INC.
IONS IONIS PHARMACEUTICALS INC.
PETS PETMED EXPRESS INC.
UTHR UNITED THERAPEUTICS CORPORATION
INSG INSEEGO CORP
INSW INTERNATIONAL SEAWAYS INC.
NMI. KIRKLAND LAKE GOLD LTD.
SNAP SNAP INC. CLASS A
AKCA AKCEA THERAPEUTICS INC.
SSRM SSR MINING INC
ZLAB ZAI LAB LTD. SPONSORED ADR
QTRX QUANTERIX CORPORATION
CUE CUE BIOPHARMA INC
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
HEAR TURTLE BEACH CORP.
EVER EVERQUOTE
ARAV ARAVIVE
DOCU DOCUSIGN INC.
MR MONTAGE RESOURCES CORP.
DSSI DIAMOND S SHIPPING
SPNS SAPIENS INTERNATIONAL CORP. N.V.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
ARCT ARCTURUS THERAPEUTICS HOLDINGS INC
LVGO LIVONGO HEALTH
SQNS SEQUANS COMMUNICATIONS ADR
CGEN COMPUGEN LTD.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch